ROSGQ (Rosetta Genomics) LT-Debt-to-Total-Asset: 0.39 (As of Jun. 2017)


What is Rosetta Genomics LT-Debt-to-Total-Asset?

Rosetta Genomics ROSGQ -99.00% LT-Debt-to-Total-Asset is 0.39 as of Jun. 2017.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Rosetta Genomics's long-term debt to total assests ratio for the quarter that ended in Jun. 2017 was 0.39.

Rosetta Genomics's long-term debt to total assets ratio increased from Jun. 2016 (0.01) to Jun. 2017 (0.39). It may suggest that Rosetta Genomics is progressively becoming more dependent on debt to grow their business.

Rosetta Genomics  (OTCPK:ROSGQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Rosetta Genomics LT-Debt-to-Total-Asset Related Terms

Rosetta Genomics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics LT-Debt-to-Total-Asset Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.31

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.31 0.39

Rosetta Genomics LT-Debt-to-Total-Asset Calculation

Rosetta Genomics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

LT Debt to Total Assets (A: Dec. 2016 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2016 )/Total Assets (A: Dec. 2016 )
=3.74/11.961
=0.31

Rosetta Genomics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2017 is calculated as

LT Debt to Total Assets (Q: Jun. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2017 )/Total Assets (Q: Jun. 2017 )
=2.394/6.207
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.39 mean?
Rosetta Genomics (ROSGQ) has a LT-Debt-to-Total-Asset of 0.39 as of Jun. 2017. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' LT-Debt-to-Total-Asset too high?
Rosetta Genomics' current LT-Debt-to-Total-Asset is 0.39.
How does Rosetta Genomics' LT-Debt-to-Total-Asset compare to TEAR and IDTA?
Rosetta Genomics' LT-Debt-to-Total-Asset of 0.39 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?
A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current LT-Debt-to-Total-Asset is 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current LT-Debt-to-Total-Asset of 0.39. The current LT-Debt-to-Total-Asset is 0.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current LT-Debt-to-Total-Asset is 0.39 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.